// Workers AI · dad joke modeIs succinylacetone a good singer? It's an acetone to be reckoned with.
 | |
| Names | |
|---|---|
| Preferred IUPAC name
4,6-Dioxoheptanoic acid | |
| Other names
Succinyl acetone | |
| Identifiers | |
3D model (JSmol) |
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.153.292 |
| EC Number |
|
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C7H10O4 | |
| Molar mass | 158.153 g·mol−1 |
| Hazards | |
| GHS labelling: | |
 | |
| Warning | |
| H315, H319, H335 | |
| P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Succinylacetone is a toxic organic compound that arises as an abnormal metabolite in tyrosine catabolism. In normal tyrosine catabolism, fumarylacetoacetate hydrolase converts fumarylacetoacetate to fumarate and acetoacetate. Deficiency of fumarylacetoacetate hydrolase leads to the accumulation of fumarylacetoacetate, which is subsequently converted to succinylacetoacetate. Succinylacetoacetate is then decarboxylated to form succinylacetone.
Patients with tyrosinemia type 1 have a congenital deficiency of fumarylacetoacetate hydrolase, resulting in the accumulation of succinylacetone in blood and urine. Elevated levels of succinylacetone, with or without elevations of tyrosine, are indicative of tyrosinemia type 1. Measurement of succinylacetone is the preferred marker in newborn screening of Tyrosinemia Type 1 due to its high sensitivity and specificity. [1] Succinylacetone can also be detected in the urine through LCMS or GCMS.
Succinylacetone also inhibits ALA dehydratase (PBG synthase), an enzyme involved in porphyrin and heme synthesis. This results in increased ALA levels and, in certain patients, precipitates acute neuropathic symptoms, similar to porphyria. Decreased heme concentration can also be seen as a result of this potent inhibition [2]
References
[edit]- ↑ de Laet C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L, et al. (January 2013). "Recommendations for the management of tyrosinaemia type 1". Orphanet Journal of Rare Diseases. 8 8. doi:10.1186/1750-1172-8-8. PMC 3558375. PMID 23311542.
- ↑ Ebert P, Hess R, Frykholm B, Tschudy D (1979). "Succinylacetone, a potent inhibitor of heme biosynthesis: effect on cell growth, heme content and δ-aminolevulinic acid dehydratase activity". Biochemical Pharmacology. 88: 1382–1390. doi:10.1016/0006-291X(79)91133-1.